Abstract
Introduction: To summarize recent analyses on the economic aspects regarding the use of PSMA-PET in prostate cancer and to evaluate the cost-effective management of patients referred to this new generation imaging to stage the disease. Methods: A comprehensive search was performed based on SCOPUS and PubMed databases to evaluate studies reporting about cost analysis in PSMA-PET. Results: Preliminary data regarding the cost-effective management of prostate cancer patients investigated with PSMA-PET have been found. These studies both explored the pre-surgery and the biochemical recurrent setting. Furthermore, separate analyses about the use hybrid PET/CT and PET/MRI scanners have been reported. Conclusion: PSMA-PET has the potential to save time and reduce costs from a patient and health-care perspective, by providing a more accurate disease staging and leading to more effective, personalized, imaging-guided approach.
| Original language | English |
|---|---|
| Pages (from-to) | 409-412 |
| Number of pages | 4 |
| Journal | Clinical and translational imaging |
| Volume | 9 |
| Issue number | 5 |
| Early online date | 2021 |
| DOIs | |
| Publication status | Published - Oct 2021 |
Keywords
- HTA PSMA
- HTA prostate cancer
- Health technology assessment
- PSMA PET
- Prostate-specific membrane antigen